Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02933255
Recruitment Status : Recruiting
First Posted : October 14, 2016
Last Update Posted : February 25, 2020
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Tracking Information
First Submitted Date  ICMJE October 13, 2016
First Posted Date  ICMJE October 14, 2016
Last Update Posted Date February 25, 2020
Actual Study Start Date  ICMJE April 18, 2017
Estimated Primary Completion Date August 1, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 4, 2020)
  • Safety - lead-in mCRPC cohort [ Time Frame: After 10 patients ]
    Detection of clinically important inflammation defined as a grade 3 diarrhea or colitis requiring steroids or anti cytokine therapy or not resolving to grade 1 or less within 28 days.
  • Evaluate changes in T-cell infiltration in the tumor after neoadjuvant treatment [ Time Frame: From baseline to 10 weeks ]
    Evaluate changes in T-cell infiltration in the tumor after neoadjuvant treatment with PROSTVAC and nivolumab, relative to changes seen in a phase 2 trial with PROSTVAC alone in the neoadjuvant setting NCT02153918 (For neoadjuvant cohort).
Original Primary Outcome Measures  ICMJE
 (submitted: October 13, 2016)
  • Safety - lead-in mCRPC cohort [ Time Frame: After 10 patients ]
  • Evaluate changes in T-cell infiltration in the tumor after neoadjuvant treatment [ Time Frame: From baseline to 10 weeks ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 16, 2017)
  • Determine the change in peripheral PSA-specific T cells in patients treated with PROSTVAC and nivolumab [ Time Frame: 3-5 years ]
  • Document any intraprostatic Treg cell infiltration with CD4+FOX-P3staining [ Time Frame: 3-5 years ]
  • Document any PSA changes secondary to vaccination, including rate of biochemical recurrence after prostatectomy [ Time Frame: 3-5 Years ]
  • Document any MRI changes secondary to treatment [ Time Frame: 3-5 years ]
  • Evaluate changes in PDL-1 expression [ Time Frame: 3-5 years ]
  • Document pathologic responses (including pathologic CR) [ Time Frame: 3-5 years ]
  • Evaluate changes in immune cell subsets in the periphery [ Time Frame: 3-5 years ]
  • Evaluate changes in soluble immune mediating factors (such as cytokines, etc.) in sera [ Time Frame: 3-5 years ]
  • Evaluate changes in circulating tumor cells levels (for mCRPCcohort only) [ Time Frame: 3-5 years ]
  • Safety (for localized prostate cancer cohorts) [ Time Frame: 3-5 years ]
Original Secondary Outcome Measures  ICMJE
 (submitted: October 13, 2016)
  • Determine the change in peripheral PSA-specific T cells in patientstreated with these vaccines [ Time Frame: 3-5 years ]
  • Document any intraprostatic Treg cell infiltration with CD4+FOX-P3staining [ Time Frame: 3-5 years ]
  • Document any PSA changes secondary to vaccination, includingrate of biochemical recurrence after prostatectomy [ Time Frame: 3-5 Years ]
  • Document any MRI changes secondary to treatment [ Time Frame: 3-5 years ]
  • Evaluate changes in PDL-1 expression [ Time Frame: 3-5 years ]
  • Document pathologic responses (including pathologic CR) [ Time Frame: 3-5 years ]
  • Evaluate changes in immune cell subsets in the periphery [ Time Frame: 3-5 years ]
  • Evaluate changes in soluble immune mediating factors (such ascytokines, etc.) in sera [ Time Frame: 3-5 years ]
  • Evaluate changes in circulating tumor cells levels (for mCRPCcohort only) [ Time Frame: 3-5 years ]
  • Safety (for localized prostate cancer cohorts) [ Time Frame: 3-5 years ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Official Title  ICMJE Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Brief Summary

Background:

The immune system is the cells and organs in the body that recognize and fight infection and cancer. The PROSTVAC vaccine might teach the immune system to find and kill certain prostate cancer cells. Nivolumab is a drug that allows the immune system to fight tumors. Itmight help PROSTVAC work better.

Objective:

To test the safety and effectiveness of the combination of PROSTVAC and nivolumab. To test this for people with castration resistant prostate cancer and then for other people with localized prostate cancer who are candidates for surgical removal of the prostate.

Eligibility:

Men ages 18 and older with prostate cancer

Design:

Participants will be screened with:

Medical history

Physical exam

Blood and urine tests

Electrocardiogram

Bone scan

CT scan or MRI

Tumor sample. This may be from a previous procedure.

All participants will get a combination of the study drugs over 8 weeks. They will have 1 visit for the initial injection then 3 booster injection / nivolumab infusion visits. Blood will be tested at these visits.

Over the next 4 weeks, some participants will have:

An exam of the large intestine through the rectum.

CT and bone scans

Standard hormonal treatment

Option to continue treatment every 3 weeks if their disease does not get worse. They will be

have scans every 12 weeks.

Other participants will have surgery to remove the prostate in week 9.

Participants will have a safety visit about a month after their last treatment. This will include a physical exam, blood tests, and possibly scans.

If their cancer progresses, participants will leave the study and may enroll in a long-term follow-up study. They will be contacted once a year to ask about their cancer and treatment.

Detailed Description

Background:

  • Immune checkpoint inhibitors interfere with the immune system s autoregulatory mechanisms, allowing for a potentially expanded and prolonged T-cell response with the possibility of greater antitumor effects.
  • Nivolumab is a fully human IgG4 monoclonal antibody that targets the PD-1 protein. Specifically, the antibody binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, thereby releasing PD-1 pathway-mediated inhibition of the immune response, including anti-tumor immune response.
  • PROSTVAC (developed by the National Cancer Institute [NCI] and licensed to Bavarian Nordic Immunotherapeutics, Mountain View, CA) is a therapeutic cancer vaccine for prostate cancer. Early studies have demonstrated immunologic efficacy and suggested clinical benefit. A phase III trial has completed accrual.
  • A previous study combining the immune checkpoint inhibitor ipilimumab and PROSTVAC suggested greater efficacy than PROSTVAC alone. Additional studies have demonstrated the potential efficacy of immunologic combination therapy with the immune checkpoint inhibitor nivolumab.
  • This study will aim to evaluate the impact of the combination of PROSTVAC and the immune checkpoint inhibitor nivolumab on the tumor microenvironment focusing on immune cell infiltration as the primary endpoint.
  • US-MRI imaging technology will be employed to sample the tumor before treatment and after radical prostatectomy.
  • The findings from this study could serve as the basis for future studies with this combination in this population of patients and more advanced disease.

Objectives:

  • Safety (For castration resistant prostate cancer (CRPC) lead-in cohort)
  • Evaluate changes in T-cell infiltration in the tumor after neoadjuvant treatment with PROSTVAC and nivolumab, relative to changes seen in a phase 2 trial with PROSTVAC alone in the neoadjuvant setting- NCT02153918 (For the neoadjuvant cohort).

Eligibility:

  • Patients must have histopathological documentation of adenocarcinoma of the prostate prior to starting this study and evaluable biopsy tissue (e.g., unstained slides or blocks) available for analysis.
  • For the castration resistant lead in cohort, if histopathological documentation is unavailable, a rising PSA and a clinical course consistent with prostate cancer would be acceptable.
  • Patients must have a performance status of 0 to 1 according to the ECOG criteria.
  • Hematological eligibility parameters (within 16 days of starting therapy):

    • Granulocyte count 1,500/mm^3
    • Platelet count 100,000/mm^3
    • Hgb greater than or equal to 8 g/dL
  • Biochemical eligibility parameters (within 16 days of starting therapy):

    • Hepatic function: Bilirubin < 1.5 mg/dl (OR in patients with Gilbert's syndrome, total bilirubin less than or equal to 3.0 mg/dL), AST and ALT less than or equal to 2.5 times upper limit of normal.
    • Creatinine less than or equal to 1.5 X ULN

Design:

  • The primary focus of this study will be to evaluate PROSTVAC and nivolumab in the neoadjuvant setting.
  • Lead-in cohort evaluating the safety and tolerability of this combination in the castration resistant setting (CRPC cohort)
  • Following this lead-in cohort in the CRPC setting, we will enroll a cohort in the neoadjuvant setting evaluating the combination of PROSTVAC and nivolumab.
  • The lead-in safety cohort will require 10 patients and the neoadjuvant cohort will require 17 evaluable patients. In order to allow for a small number of inevaluable patients, the accrual ceiling will be set to 29 patients.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prostate Cancer
Intervention  ICMJE
  • Biological: PROSTVAC-V/F
    PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10^8 infectious units; PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10^9 infectious units.
  • Drug: Nivolumab
    Nivolumab is to be administered as a flat dose of 240 mg over approximately 60-minutes via IV infusion.
Study Arms  ICMJE
  • Experimental: Lead-in mCRPC Cohort
    PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4, 6 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Patients will undergo sigmoidoscopies on week 9 and restaging scans on week 11. If no PD, option to continue treatment every 3 weeks until intolerance or progression (evaluated radiographically every 12 weeks).
    Interventions:
    • Biological: PROSTVAC-V/F
    • Drug: Nivolumab
  • Experimental: Neoadjuvant Cohort
    PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Patients will undergo prostatectomy on week 9.
    Interventions:
    • Biological: PROSTVAC-V/F
    • Drug: Nivolumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 16, 2017)
29
Original Estimated Enrollment  ICMJE
 (submitted: October 13, 2016)
65
Estimated Study Completion Date  ICMJE August 1, 2022
Estimated Primary Completion Date August 1, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE
  • INCLUSION CRITERIA:

For the neoadjuvant cohort, patients must have histopathological documentation of adenocarcinoma of the prostate prior to starting this study and evaluable biopsy tissue (e.g., unstained slides or blocks) available for analysis. If evaluable tissue is not available, the patient must agree to undergo a pre-vaccination prostate biopsy on study. For the CRPC lead in cohort, if histopathological documentation is unavailable, a rising PSA and a clinical course consistent with prostate cancer would be acceptable.

  • Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of PROSTVAC in combination with nivolumab, ipilimumab or both in patients <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
  • ECOG performance status of 0 or 1.
  • Patients must not have other active invasive malignancies within the past 2 years (with the exception of non-melanoma skin cancers) (for CRPC cohort only).
  • Patients must be willing to travel to the study site for follow-up visits
  • All patients who have received prior vaccination with vaccinia virus (for smallpox immunization) must not have a history of serious adverse reaction to the vaccine.
  • The effects of PROSTVAC in combination nivolumab, ipilimumab or both on the developing human fetus are unknown. For this reason men must agree to use adequate contraception (abstinence, vasectomy) or female partner must use (intrauterine device (IUD), hormonal [birth control, pills, injections, or implants], tubal ligation] prior to study entry and for up to 7 months after the last dose.
  • Patients must understand and sign informed consent that explains the neoplastic nature of their disease, the procedures to be followed, the experimental nature of the treatment, alternative treatments, potential risks and toxicities, and the voluntary nature of participation.
  • Patients must have normal organ and marrow function as defined below:

    • hemoglobin greater than or equal to 8 g/dL
    • granulocytes greater than or equal to 1,500/mcL
    • platelets greater than or equal to 100,000/mcL
    • total bilirubin < 1.5 mg/dL (or less than or equal to 3.0 mg/dL in patients with Gilbert syndrome)
    • AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of normal
    • creatinine less than or equal to 1.5 X ULN
  • For the lead in cohort:

    • Castrate testosterone level (<50ng/dl or 1.7nmol /L)
    • Progressive disease at study entry defined as one or more of the following criteria occurring in the setting of castrate levels of testosterone:

      • Radiographic progression defined as any new or enlarging bone lesions or growing lymph node disease, consistent with prostate cancer OR
      • PSA progression defined by sequence of rising values separated by >1 week (2 separate increasing values over a minimum of 2ng/ml (PCWG2 PSA eligibility criteria). If patients had been on flutamide, PSA progression is documented 4 weeks or more after withdrawal. For patients on bicalutamide or nilutamide disease progression is documented 6 or more weeks after withdrawal.
    • Patients must agree to continuation of androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone agonist/antagonist or bilateral orchiectomy
  • For all other cohorts:

    • Patients must be a surgical candidate for radical prostatectomy based on standard workup of PSA, biopsy results, and if necessary supplemental imaging.
    • Patients must have chosen radical prostatectomy as their definitive treatment of choice for management of their prostate cancer.
    • No systemic steroid or steroid eye drop use within 2 weeks prior to initiation of experimental therapy. Limited doses of systemic steroids to prevent IV contrast, allergic reaction or anaphylaxis (in patients who have known contrast allergies) are allowed.

EXCLUSION CRITERIA:

  • Prior splenectomy.
  • The recombinant vaccinia vaccine should not be administered if the following apply to either recipients or, for at least 3 weeks after vaccination, their close household contacts (Close household contacts are those who share housing or have close physical contact):

    • persons with active or a history of eczema or other eczematoid skin disorders
    • those with other acute, chronic or exfoliative skin conditions (e.g., atopic dermatitis, burns, impetigo, varicella zoster, severe acne or other open rashes or wounds) until condition resolves
    • pregnant or nursing women; children under 3 years of age
  • Patients should have no evidence, as listed below, of being immunocompromised:

    • HIV positivity due to the potential for decreased tolerance and risk for severe side effects.
    • Hepatitis B or C positivity.
  • Concurrent use of systemic steroids or steroid eye drops. This is to avoid immunosuppression which may lead to potential complications with vaccinia (priming vaccination). Nasal, topical or inhaled steroid use is permitted.
  • Patients with known allergy to eggs or to compounds with a similar chemical or biologic composition to PROSTVAC, ipilimumab or nivolumab.
  • No prior immune checkpoint inhibitors (e.g., anti-CTLA4, anti-PD-1 or anti-PDL1) are allowed.
  • Other serious intercurrent illness.
  • Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment) or New York Heart Association class II IV congestive heart failure.
  • Patients with significant autoimmune disease that is active or potentially life threatening if activated.
  • Patients with clinically significant cardiomyopathy requiring treatment.
  • Patients with ongoing toxicities related to prior therapies targeting T cell coregulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody are excluded
  • No transfusion of blood or blood products within 2 weeks and no G-CSF or GM-CSF within 2 weeks prior to initiations of experimental therapy.
  • Contraindication to biopsy or prostatectomy (for sequential neoadjuvant cohorts only):

    • Bleeding disorders
    • Artificial heart valve
    • PT/PTT greater than or equal to 1.5 in patients not taking anticoagulation. Patients on anticoagulation (e.g. enoxaparin, oral anticoagulants) are eligible regardless of PT/PTT. Prior to biopsy, anticoagulation will be held per standard practice.
  • For patients with localized prostate cancer contraindication to MRI:

    • Patients weighing >136 kilograms (weight limit for the scanner tables)
    • Allergy to MR contrast agent
    • Patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices
  • History of radiation proctitis (for lead-in CRPC cohort only)
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Guinevere Chun, R.N. (240) 760-7967 gchun@mail.nih.gov
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02933255
Other Study ID Numbers  ICMJE 170007
17-C-0007
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
Study Sponsor  ICMJE National Cancer Institute (NCI)
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: James L Gulley, M.D. National Cancer Institute (NCI)
PRS Account National Institutes of Health Clinical Center (CC)
Verification Date February 3, 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP